Monday 20 February 2012

Par Pharmaceutical Completes Acquisition of Edict Pharmaceuticals

Par Pharmaceutical Companies, Inc. (NYSE: PRX) announced  that it has completed the acquisition of privately-held Edict Pharmaceuticals Private Limited, an India-based developer and manufacturer of generic pharmaceuticals.

Edict is a Chennai, India-based developer and manufacturer of solid oral dosage generic pharmaceuticals with a highly-skilled research and development team and strong product pipeline focused on niche first-to-file, first-to-market products. Edict currently has 11 ANDAs filed with the U.S. FDA.

About Par Pharmaceutical Companies, Inc.Par Pharmaceutical Companies, Inc. is a U.S.-based specialty pharmaceutical company. Through its wholly-owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals, it develops, manufactures and markets high barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals. For press release and other company information, visit www.parpharm.com.
Read more here: http://www.bradenton.com/2012/02/17/3883443/par-pharmaceutical-completes-acquisition.html#storylink=cpy

No comments:

Post a Comment